Filing Details
- Accession Number:
- 0001140361-23-040322
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-17 21:30:51
- Reporting Period:
- 2023-08-15
- Accepted Time:
- 2023-08-17 21:30:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1368514 | Adma Biologics Inc. | ADMA | Biological Products, (No Disgnostic Substances) (2836) | 562590442 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1542517 | S Adam Grossman | C/O Adma Biologics, Inc. 465 State Route 17 Ramsey NJ 07446 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-08-15 | 212,500 | $1.67 | 2,735,585 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-15 | 277,131 | $2.35 | 3,012,716 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-15 | 277,604 | $2.92 | 3,290,320 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-15 | 400,000 | $3.22 | 3,690,320 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-15 | 350,000 | $3.71 | 4,040,320 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-15 | 583,224 | $3.66 | 4,623,544 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-15 | 510,469 | $4.54 | 4,113,075 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-08-15 | 1,589,987 | $4.61 | 2,523,088 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-08-16 | 3 | $4.39 | 2,523,085 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Stock | Disposition | 2023-08-15 | 212,500 | $1.67 | 212,500 | $1.67 |
| Common Stock | Common Stock | Disposition | 2023-08-15 | 277,131 | $2.35 | 277,131 | $2.35 |
| Common Stock | Common Stock | Disposition | 2023-08-15 | 277,604 | $2.92 | 277,604 | $2.92 |
| Common Stock | Common Stock | Disposition | 2023-08-15 | 400,000 | $3.22 | 400,000 | $3.22 |
| Common Stock | Common Stock | Disposition | 2023-08-15 | 350,000 | $3.71 | 350,000 | $3.71 |
| Common Stock | Common Stock | Disposition | 2023-08-15 | 583,224 | $3.66 | 583,224 | $3.66 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 387,500 | 2032-03-07 | No | 4 | M | Direct | |
| 181,569 | 2031-02-25 | No | 4 | M | Direct | |
| 47,396 | 2030-02-28 | No | 4 | M | Direct | |
| 0 | 2029-01-23 | No | 4 | M | Direct | |
| 0 | 2028-02-09 | No | 4 | M | Direct | |
| 0 | 2027-06-06 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,143,426 | Indirect | See Footnote |
| Common Stock | 580,957 | Indirect | See Footnote |
Footnotes
- Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.495 to $4.63, inclusive.
- Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
- (continued from footnote 2) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;
- (continued from footnote 3) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
- These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
- These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
- The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.
- The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.
- The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.
- The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023
- The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.
- The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021.
Billionaire Hedge Funds
